LONIDAMINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY
LONIDAMINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY
复制标题
DOI：
10.1177/030089169107700113
复制
发表时间：
1991-02-28
期刊：
影响因子：
--
通讯作者：
PAGA, C
中科院分区：
文献类型：
--
作者：
CONTU, A;OLMEO, NA;PAGA, C
对吲唑-羧酸衍生物、具有抗肿瘤活性的新药氯硝胺在非小细胞肺癌(NSCLC)中的活性进行了评价。25例接受或未接受治疗的非小细胞肺癌患者接受氯硝胺450 mg/d口服。达到进步的程度。客观反应：部分反应3例(12%)，轻微反应3例(12%)，平均持续时间13.7周。平均疗程20周(4~97+)。根据药物的特点，未观察到骨髓毒性，最显著的副作用是肌肉痛和轻微的睾丸疼痛。
The activity of lonidamine (a derivative of indazole-carboxylic acid and a new drug with a characteristic antitumor activity) was evaluated in non-small-cell lung cancer (NSCLC). Twenty-five patients with NSCLC with or without prior treatment recieved lonidamine at the dose of 450 mg/daily p.o. up to progression. Objective responses obtained were: 3 (12%) partial responses and 3 (12%) minor responses with a mean duration of 13.7 weeks for partial responses. Mean duration of treatment was 20 weeks (range 4-97+). During to the drug's characteristics, bone marrow toxicity was not observed; myalgia and mild testicular pain were the most significant side effects.